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Androgen deprivation therapy (ADT) has been universally
accepted as the initial treatment choice in advanced or metastatic
prostate cancer. However, most patients invariably will progress on
ADT and become resistant to castration, leading to poor outcomes
and death. Recent new data presented on the earlier use of
chemotherapy in addition to ADT, in the hormone sensitive meta-
static prostate cancer setting, may potentially change management
paradigms. However, the beneﬁt of its efﬁcacy needs to be balanced
by judicious use in deﬁned populations due to potential toxicities.
Here, arguments for and against its use are presented.
2. Chemohormonal combination therapy should be used as
ﬁrst-line/upfront therapy in hormone sensitive M1 disease
Chemotherapy (intravenous docetaxel) was ﬁrst approved for
the treatment of metastatic castrate resistant prostate cancer
(mCRPC) in 2004 after it showed improvement in survival and
quality of life in this group of patients. Based on its efﬁcacy in the
mCRPC setting, chemohormonal therapy has recently been tested
in the hormone sensitive setting. The rationale hypothesized was
that this approach would deplete de-novo testosterone clones
early, and would enable patients to receive chemotherapy before
they experience a drop in performance status due to disease
progression.
The ﬁrst study to explore this was the GETUG-AFU 15 study
which showed no overall survival beneﬁt among patients who
received chemohormonal combination or hormonal therapy alone.1
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p2287-8882 e2287-903Xoverall survival (OS) (57.6 months vs 44.0 months, HR ¼ 0.61, 95%
CI 0.47e0.80).2 This improvement was seen particularly in a group
of patients who were having high volume disease, which was
deﬁned as having visceral metastasis, or four or more bone
metastases including one metastasis outside of the axial skeleton
(HR ¼ 0.60, 95%CI 0.45e0.81). The median OS improvement in this
group was 17 months with the chemohormonal therapy.
The ﬁndings of CHAARTED were further supported by the
STAMPEDE study results presented recently at ASCO 2015. In this
multi-arm study (which included a subset of M0 patients), pa-
tients on the chemohormonal therapy arm had a longer overall
survival (OS) beneﬁt (77 months vs 66 months, HR ¼ 0.76, 95%CI
0.63e0.91).3 A longer survival beneﬁt of 22 months (65 months
vs 43 months; HR¼0.73, 95%CI 0.59e0.89) was seen in the
subset of patients with metastatic disease. These data provide
compelling evidence to support the use of chemohormonal
combination as upfront therapy in metastatic hormone sensitive
disease.3. Chemohormonal combination therapy may not be the best
ﬁrst-line/upfront option for the treatment of hormone
sensitive M1 disease
Chemotherapy using docetaxel has been accepted as one of the
standard treatments formCRPC patients. Recently, chemohormonal
combination therapy has been suggested as ﬁrst-line therapy in
hormone sensitive metastatic prostate cancer patients (CHAARTED
& STAMPEDE vs GETUG trials). Nevertheless, there is a need to re-
evaluate its relevance, beneﬁts and tolerability in daily practice
within Asia, due to innate ethnic differences that could affect data
applicability. In the CHAARTED trial, combination therapy
improved OS compared to androgen deprivation therapy (ADT)
alone.2 However, in the GETUG-AFU 15 trial, which was carried out
in a similar patient group, there was no difference between the two
groups (median OS: 58.9 vs 54.2 months; p ¼ 0.955).1 It is also
worth noting that, despite being a negative trial, the GETUG study
allowed higher number of cycles of chemotherapy than CHAARTED
(9 vs 6 cycles).
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chemotherapy have been reported in Asian patients and older
patients. There are twice as many incidences of Grade 3 or 4
neutropaenia in the Asian study cohort than in the Caucasian
group.4,5 Asian patients may also require lower doses of chemo-
therapy. In a multicenter retrospective review in Hong Kong, two
in every ﬁve patients were given a non-standard dose.6 In addi-
tion, twenty percent of patients needed their initial dose modiﬁed
because of haematological toxicities.7 Dose modiﬁcations are also
needed for many elderly patients (age 80 years and older).8 Lastly,
there is no outcome data supporting combination over sequencing
of treatments in metastatic hormone-sensitive prostate cancer
patients, such as the head-to-head comparison of ﬁrst-line ADT
followed by docetaxel vs ﬁrst-line ADT with docetaxel. Therefore,
chemotherapy may not yet be a viable option for ﬁrst-line treat-
ment in hormone sensitive metastatic prostate cancer patients in
Asia. Asian patients have shown better response to hormonal
manipulation than Caucasians. The use of ADT in hormone sen-
sitive disease showed a relative response rate of 90%.9 There was
also a signiﬁcant OS beneﬁt with combined androgen blockade
with bicalutamide compared to luteinising hormone-releasing
hormone monotherapy.94. Conclusion
Strong evidence of efﬁcacy in two large clinical trials has been
presented, which is likely to drive the use of chemotherapy for
hormone sensitive metastatic prostate cancer. However, there may
be a need for newer biomarkers (including molecular markers) to
better risk-stratify patients, in order to balance the beneﬁts and
risks of toxicity. Issues related to possible lower tolerability, access
and cultural attitude to chemotherapy amongst Asian patients de-
serves further study.Conﬂicts of interest
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